Drug Profile
Maplirpacept - Trillium Therapeutics
Alternative Names: CD47Fc; PF-07901801; SIRPa-IgG4-Fc; TTI-622Latest Information Update: 16 Apr 2024
Price :
$50
*
At a glance
- Originator The Hospital for Sick Children; University Health Network
- Developer Incyte Corporation; MorphoSys; Pfizer
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action CD47 antigen inhibitors; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Haematological malignancies
- Phase I/II Acute myeloid leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Ovarian cancer
- Phase I Lymphoma; Non-Hodgkin's lymphoma
- Preclinical Solid tumours
Most Recent Events
- 15 Feb 2024 Pfizer terminates a phase I/II trial in Ovarian cancer (Combination therapy, Second-line therapy or greater) in USA (IV) due to a business decision was made by Pfizer to terminate and remove the Phase II expansion of this study for administrative reasons (NCT05261490)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)